Live Breaking News & Updates on Royalty Purchase|Page 6

Stay updated with breaking news from Royalty purchase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

/PRNewswire/ Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today. ....

United States , Ivor Royston , Cheryla Madsen , Kristen Cunanan , Thomas Darcy , Pierluigi Porcu , Joyce Allaire , Nicole Onetto , Dan Chevallard , Barryj Simon , Stephen Rubino , Company Contact , Regulatory Affairs , Drug Administration , Md Thomas Jefferson University , Trademark Office , Development Expenses , Sunesis Pharmaceuticals Inc , Phd Stanford University School Of Medicine , Viracta Therapeutics Inc , Viracta Therapeutics , Chief Executive Officer , United States Food , American Society , Hematology Annual Meeting , Sunesis Pharmaceuticals ,

Aptevo Therapeutics Reports First Quarter 2021 Financial Results

Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing
SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ( Aptevo or the Company ) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today reported its financial results for the quarter ended March 31, 2021.
We are pleased to report progress in the clinical trial of our ADAPTIR platform candidate APVO436, with the dose limiting toxicity (DLT) evaluation in cohorts 1 through 9 now completed and 44 patients enrolled to date in cohorts 1-10. We remain confident in the clinical impact potential of APVO436 and our platform technologies, and look forward to sharing interim data readouts from our ongoing APVO436 study later ....

Marvin White , Exchange Commission , Development Expenses , Aptevo Therapeutics Inc , Healthcare Royalty Management , Pfizer Inc , Aptevo Biotherapeutics , Advances Phase , Acute Myeloid Leukemia , High Grade Myelodysplastic Syndrome , Aptevo Therapeutics , Results Summary , Royalty Purchase Agreement , Investment Amount , Milestone Amounts , Midcap Financial , Definitive Agreement , Royalty Purchase , Administrative Expenses , Saol Therapeutics , Hyperimmune Business , Future Royalties , Three Months Ended March , Private Securities Litigation Reform Act , Annual Report , Delia Cannan ,